Overview

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2030-06-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to evaluate the efficacy of gilteritinib as induction therapy in FLT3-positive adult acute myeloid leukemia patients. The main question it aims to answer is: Is gilteritinib in combination to chemotherapy able to improve the complete remission rate of FLT3-positive AML? Participants will receive up to 2 induction cycles with gilteritinib in combination with FLAI (fludarabine, cytarabine, idarubicine) and up to 3 consolidation cycles with gilteritinib and high-dose cytarabine.

Phase:

PHASE2

Details

Lead Sponsor:

Gruppo Italiano Malattie EMatologiche dell'Adulto

Treatments:

gilteritinib